Acute myeloid leukaemia (AML)

Indication for Idarubicin

Population group: Suitable for both men and women, only adults (18 years old or older)

For the treatment of acute myeloid leukaemia (AML), for remission induction in untreated patients or for remission induction in relapsed or refractory patients.

For this indication, competent medicine agencies globally authorize below treatments:

8-12 mg/m² once daily for 3-5 days

Route of admnistration

Intravenous

Defined daily dose

8 - 12 mg per m² of body surface area (BSA)

Dosage regimen

From 8 To 12 mg per m² of body surface area (BSA) once every day

Detailed description

12 mg/m²/day i.v. daily for 3 days in combination with cytarabine or 8 mg/m²/day i.v. daily for 5 days with/without combination.

Active ingredient

Idarubicin is a DNA intercalating anthracycline which interacts with the enzyme topoisomerase II and has an inhibitory effect on nucleic acid synthesis. Idarubicin has been shown to have a higher potency with respect to daunorubicin and to be an effective agent against murine leukaemia and lymphomas both by i.v. and oral routes.

Read more about Idarubicin

Related medicines

Summary of Product Characteristics (SPC) 2018: ZAVEDOS Powder for solution for injection
Summary of Product Characteristics (SPC) 2018: ZAVEDOS Capsules

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner